Search Results For:
- Issue:
- Equitable Access | Access plans & principles
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Product development partnership
Vaccine
Early clinical (through Phase 2)
BMGF - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Industry
Drug
Preclinical
BMGF - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
2017
Funder
Industry
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
BMGF - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
CARB-X Research Subaward Agreement (for-profit)
2019
Funder
Industry
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
Funder Development Partnering Agreement Template
2018
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation Sample Grant Terms & Conditions
2019
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
Academic Institution - Company, Research Collaboration Agreement
2016
Academic institution
Industry
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
2021
Academic institution
Multilateral organization
Multilateral organization
Drug
Preclinical
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[issue] => Array
(
[0] => equitable-access
)
)
[filters] => Array
(
[provision] => Array
(
[issue] => Array
(
[0] => equitable-access
)
)
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => equitable-access
)
)
)
)
[text_agreement_args] =>
[text_provision_args] =>
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => equitable-access
)
)
)
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => equitable-access
)
)
)
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[taxonomy] => issue
[term] => equitable-access
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
[0] => Array
(
[taxonomy] => issue
[terms] => Array
(
[0] => equitable-access
)
[field] => slug
[operator] => IN
[include_children] => 1
)
)
[relation] => AND
[table_aliases:protected] => Array
(
[0] => wpry_term_relationships
)
[queried_terms] => Array
(
[issue] => Array
(
[terms] => Array
(
[0] => equitable-access
)
[field] => slug
)
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT wpry_posts.*
FROM wpry_posts LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id)
WHERE 1=1 AND (
wpry_term_relationships.term_taxonomy_id IN (101)
) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
GROUP BY wpry_posts.ID
ORDER BY wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4696
[post_author] => 5
[post_date] => 2022-04-26 11:05:38
[post_date_gmt] => 2022-04-26 11:05:38
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:48:01
[post_modified_gmt] => 2022-04-26 14:48:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4680
[post_author] => 5
[post_date] => 2022-04-25 11:17:54
[post_date_gmt] => 2022-04-25 11:17:54
[post_content] =>
[post_title] => BMGF - Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:14:11
[post_modified_gmt] => 2022-04-26 15:14:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4680
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:22:54
[post_modified_gmt] => 2022-04-18 13:22:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4519
[post_author] => 5
[post_date] => 2022-03-25 12:48:09
[post_date_gmt] => 2022-03-25 12:48:09
[post_content] =>
[post_title] => Gates Foundation Sample Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-grant-terms-conditions
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-25 12:48:09
[post_modified_gmt] => 2022-03-25 12:48:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4519
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4516
[post_author] => 5
[post_date] => 2022-03-23 09:07:57
[post_date_gmt] => 2022-03-23 09:07:57
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-23 09:09:43
[post_modified_gmt] => 2022-03-23 09:09:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4516
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:45:11
[post_modified_gmt] => 2022-01-28 13:45:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 4077
[post_author] => 5
[post_date] => 2022-01-11 07:20:11
[post_date_gmt] => 2022-01-11 07:20:11
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 10:38:59
[post_modified_gmt] => 2022-04-01 10:38:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4077
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 4060
[post_author] => 5
[post_date] => 2022-01-07 09:40:49
[post_date_gmt] => 2022-01-07 09:40:49
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 09:40:49
[post_modified_gmt] => 2022-01-07 09:40:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4060
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 3375
[post_author] => 5
[post_date] => 2021-06-30 16:36:27
[post_date_gmt] => 2021-06-30 16:36:27
[post_content] =>
[post_title] => BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:35:36
[post_modified_gmt] => 2021-08-10 10:35:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3375
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 3335
[post_author] => 6
[post_date] => 2021-06-30 12:20:18
[post_date_gmt] => 2021-06-30 12:20:18
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:35:14
[post_modified_gmt] => 2021-08-10 10:35:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3335
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 10:11:21
[post_modified_gmt] => 2022-04-01 10:11:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 1220
[post_author] => 6
[post_date] => 2020-05-22 20:05:59
[post_date_gmt] => 2020-05-22 20:05:59
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 15:23:28
[post_modified_gmt] => 2022-01-11 15:23:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 1206
[post_author] => 6
[post_date] => 2020-05-22 19:37:27
[post_date_gmt] => 2020-05-22 19:37:27
[post_content] =>
[post_title] => Gates Foundation Sample Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-global-access-commitment-and-humanitarian-license
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:41:46
[post_modified_gmt] => 2022-03-28 10:41:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 1202
[post_author] => 6
[post_date] => 2020-05-22 19:28:49
[post_date_gmt] => 2020-05-22 19:28:49
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:52:26
[post_modified_gmt] => 2021-08-10 10:52:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 1199
[post_author] => 6
[post_date] => 2020-05-22 19:21:57
[post_date_gmt] => 2020-05-22 19:21:57
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 08:55:34
[post_modified_gmt] => 2022-04-01 08:55:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 1156
[post_author] => 6
[post_date] => 2020-05-21 23:10:39
[post_date_gmt] => 2020-05-21 23:10:39
[post_content] =>
[post_title] => WHO Standard Framework Memorandum of Understanding
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-standard-framework-memorandum-of-understanding
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 12:11:17
[post_modified_gmt] => 2021-12-07 12:11:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 16
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4696
[post_author] => 5
[post_date] => 2022-04-26 11:05:38
[post_date_gmt] => 2022-04-26 11:05:38
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:48:01
[post_modified_gmt] => 2022-04-26 14:48:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 16
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] => 1
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 986c1c51f50d806818d5067908d8f7f0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_agreement_q_rslts] =>
[text_provision_q_rslts] =>
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 4696
[post_author] => 5
[post_date] => 2022-04-26 11:05:38
[post_date_gmt] => 2022-04-26 11:05:38
[post_content] =>
[post_title] => BMGF – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 14:48:01
[post_modified_gmt] => 2022-04-26 14:48:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4680
[post_author] => 5
[post_date] => 2022-04-25 11:17:54
[post_date_gmt] => 2022-04-25 11:17:54
[post_content] =>
[post_title] => BMGF - Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-26 15:14:11
[post_modified_gmt] => 2022-04-26 15:14:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4680
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:22:54
[post_modified_gmt] => 2022-04-18 13:22:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4519
[post_author] => 5
[post_date] => 2022-03-25 12:48:09
[post_date_gmt] => 2022-03-25 12:48:09
[post_content] =>
[post_title] => Gates Foundation Sample Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-sample-grant-terms-conditions
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-25 12:48:09
[post_modified_gmt] => 2022-03-25 12:48:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4519
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4516
[post_author] => 5
[post_date] => 2022-03-23 09:07:57
[post_date_gmt] => 2022-03-23 09:07:57
[post_content] =>
[post_title] => CARB-X Research Subaward Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-23 09:09:43
[post_modified_gmt] => 2022-03-23 09:09:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4516
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:45:11
[post_modified_gmt] => 2022-01-28 13:45:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 4077
[post_author] => 5
[post_date] => 2022-01-11 07:20:11
[post_date_gmt] => 2022-01-11 07:20:11
[post_content] =>
[post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 10:38:59
[post_modified_gmt] => 2022-04-01 10:38:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4077
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 4060
[post_author] => 5
[post_date] => 2022-01-07 09:40:49
[post_date_gmt] => 2022-01-07 09:40:49
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-07 09:40:49
[post_modified_gmt] => 2022-01-07 09:40:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4060
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 3375
[post_author] => 5
[post_date] => 2021-06-30 16:36:27
[post_date_gmt] => 2021-06-30 16:36:27
[post_content] =>
[post_title] => BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:35:36
[post_modified_gmt] => 2021-08-10 10:35:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3375
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 3335
[post_author] => 6
[post_date] => 2021-06-30 12:20:18
[post_date_gmt] => 2021-06-30 12:20:18
[post_content] =>
[post_title] => BMGF – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:35:14
[post_modified_gmt] => 2021-08-10 10:35:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3335
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 10:11:21
[post_modified_gmt] => 2022-04-01 10:11:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 1220
[post_author] => 6
[post_date] => 2020-05-22 20:05:59
[post_date_gmt] => 2020-05-22 20:05:59
[post_content] =>
[post_title] => Academic Institution - Company, Research Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => redacted-collaboration-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-11 15:23:28
[post_modified_gmt] => 2022-01-11 15:23:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 1206
[post_author] => 6
[post_date] => 2020-05-22 19:37:27
[post_date_gmt] => 2020-05-22 19:37:27
[post_content] =>
[post_title] => Gates Foundation Sample Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-global-access-commitment-and-humanitarian-license
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:41:46
[post_modified_gmt] => 2022-03-28 10:41:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 1202
[post_author] => 6
[post_date] => 2020-05-22 19:28:49
[post_date_gmt] => 2020-05-22 19:28:49
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-10 10:52:26
[post_modified_gmt] => 2021-08-10 10:52:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 1199
[post_author] => 6
[post_date] => 2020-05-22 19:21:57
[post_date_gmt] => 2020-05-22 19:21:57
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 08:55:34
[post_modified_gmt] => 2022-04-01 08:55:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1199
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 1156
[post_author] => 6
[post_date] => 2020-05-21 23:10:39
[post_date_gmt] => 2020-05-21 23:10:39
[post_content] =>
[post_title] => WHO Standard Framework Memorandum of Understanding
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => who-standard-framework-memorandum-of-understanding
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 12:11:17
[post_modified_gmt] => 2021-12-07 12:11:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[invalid_get] =>
[is_text_search] =>
[has_agreement_filters] =>
[has_any_agreement_filter] => Array
(
)
[found_agreements] =>
[has_provision_filters] => 1
[found_provisions] => 1
[lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
[lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
[lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
[lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
[lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
[lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
[lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
[issues_by_id:GHIAA2019\MapguideSearch:private] => Array
(
[101] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 16
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[100] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 16
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[66] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 6
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[53] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[84] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 46
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[271] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[72] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 28
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[281] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 20
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[46] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[92] => WP_Term Object
(
[term_id] => 92
[name] => Exploitation of results
[slug] => exploitation-results
[term_group] => 0
[term_taxonomy_id] => 92
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 31
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[278] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 30
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[80] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 48
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[257] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 31
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[109] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 19
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[48] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[50] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[87] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of background IP
[slug] => ownership-background-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 23
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[89] => WP_Term Object
(
[term_id] => 89
[name] => Ownership of results
[slug] => ownership-results
[term_group] => 0
[term_taxonomy_id] => 89
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 39
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[70] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 30
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[102] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 9
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[268] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 20
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[49] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[90] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 32
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[290] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 23
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[56] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 25
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[81] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 33
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[86] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 18
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[52] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[76] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 32
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[74] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 31
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[282] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 16
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[88] => WP_Term Object
(
[term_id] => 88
[name] => Use of background IP
[slug] => use-background-ip
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 34
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
)
[issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
(
[equitable-access] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 16
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[pricing] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 16
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[benefit-revenue-sharing] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 6
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[business-model] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[confidentiality] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 46
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[donation] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[effect-of-termination] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 28
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[ensuring-continuity] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 20
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[access-to-medicines] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[exploitation-results] => WP_Term Object
(
[term_id] => 92
[name] => Exploitation of results
[slug] => exploitation-results
[term_group] => 0
[term_taxonomy_id] => 92
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 31
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[roles-responsibilities] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 30
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[indemnity] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 48
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[information-sharing-information-sharing] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 31
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[insurance] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 19
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[ip-ownership] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[liability] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[ownership-background-ip] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of background IP
[slug] => ownership-background-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 23
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[ownership-results] => WP_Term Object
(
[term_id] => 89
[name] => Ownership of results
[slug] => ownership-results
[term_group] => 0
[term_taxonomy_id] => 89
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 39
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[royalties-and-payments] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 30
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[outbreak-preparedness] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 9
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[supply-purchase-of-products] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 20
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[information-sharing] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[protection-results] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 32
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[publication-of-results] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 23
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[regulatory-strategy] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 25
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[warranties] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 33
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[technology-transfer] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] =>
[parent] => 49
[count] => 18
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[term-and-termination] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[term-of-agreement] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 32
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[termination-and-withdrawal] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 31
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[territory-access-commitments] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 16
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[use-background-ip] => WP_Term Object
(
[term_id] => 88
[name] => Use of background IP
[slug] => use-background-ip
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 34
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
)
[filter_issues:GHIAA2019\MapguideSearch:private] => Array
(
[0] => equitable-access
)
)
